2019 年 31 巻 181 号 p. SE61-SE62
We achieved in functioning the “glycan pattern recognition” in vivo, by clusterizing various N-glycans through efficient synthetic transformation, i.e., RIKEN click reaction. Such “glycan pattern recognition” could control the interaction with the target cells, organs and cancers, as well as regulate the excretion pathways in mice. Furthermore, we performed for the first time the metal catalyzed reaction at the targeted organs in mice, by rapidly carrying the metal catalyst using the glycan-based drug delivery system. We thus developed the next-generation strategy from the glycochemical biology, termed as “Therapeutic In Vivo Synthetic Chemistry”, where the activities of drugs or other bioactive molecules could be elicited without off-targeting problems by directly synthesizing them at the targeted diseases.
